UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission
file number:
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) | |
| (Address of principal executive office) | (Zip Code) |
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of May 13, 2026, there were shares of the registrants common stock, par value $ per share, outstanding.
Exchangeable and Special Voting Shares:
As of May 13, 2026, there were outstanding 77,530,617 exchangeable shares of BST Sub ULC, a wholly owned subsidiary of the registrant. The exchangeable shares are exchangeable for an equal number of the registrants common stock, and carry rights substantially equivalent to the Company’s common stock, including rights to dividends, liquidation preferences, and voting (via a Special Voting Preferred Stock held by a trustee).
TABLE OF CONTENTS
| 2 |
PART I – FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
STREAMEX CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Par Value and Share Amounts)
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Sales tax receivable | ||||||||
| Due from related party | ||||||||
| Marketable securities | ||||||||
| Other assets held for sale – restricted gold | ||||||||
| Other assets held for sale – gold | ||||||||
| Prepaid expenses and other assets | ||||||||
| Total current assets | ||||||||
| Non-current assets: | ||||||||
| Other assets held at cost – gold | ||||||||
| Property and equipment, net | ||||||||
| Intangible assets, net | ||||||||
| Goodwill | ||||||||
| Total non-current assets | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses, including $ | $ | $ | ||||||
| Dividends payable | ||||||||
| Convertible debentures, net | ||||||||
| Embedded derivative liability | ||||||||
| Total current liabilities | ||||||||
| Deferred tax liability | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 16) | ||||||||
| Mezzanine equity | ||||||||
| Redeemable Series C 9% Convertible Preferred Stock, $ par value, $ | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $ par value, authorized shares, designated shares of Series A, shares of Series B, shares of Series C, shares of Series D, shares of Series E, shares of Series F Preferred Stock and | ||||||||
| Common stock, $ par value, authorized shares, and issued and outstanding as of March 31, 2026, and December 31, 2025, respectively. | ||||||||
| Additional paid-in-capital | ||||||||
| Accumulated other comprehensive (loss) income | ( | ) | ||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity attributable to Streamex Corp. | ||||||||
| Non-controlling interest | ||||||||
| Total stockholders’ equity | ||||||||
| Total liabilities, mezzanine equity and stockholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements
| 3 |
STREAMEX CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(In Thousands, Except Par Value and Share Amounts)
| For the Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Revenue | $ | $ | ||||||
| Operating expenses: | ||||||||
| Research and development | ||||||||
| General and administrative | ||||||||
| Depreciation and amortization | ||||||||
| Total operating expenses | ||||||||
| Loss from operations | ( | ) | ( | ) | ||||
| Other income (expense): | ||||||||
| Interest expense, net | ( | ) | ||||||
| Realized gain on sale of gold | ||||||||
| Realized gain on marketable securities | ||||||||
| Change in fair value of marketable securities | ( | ) | ||||||
| Change in fair value of embedded derivative | ||||||||
| Realized loss on extinguishment of convertible debentures | ( | ) | ||||||
| Realized loss on investment | ( | ) | ||||||
| Gain on settlement and forgiveness of debt | ||||||||
| Other income (expense), net | ( | ) | ||||||
| Total other income (expense), net | ( | ) | ||||||
| Loss before income taxes | ( | ) | ( | ) | ||||
| Income taxes (benefit) | ( | ) | ||||||
| Net loss | ( | ) | ( | ) | ||||
| Non-controlling interest | ( | ) | ||||||
| Net loss attributable to Streamex Corp. | ( | ) | ( | ) | ||||
| Preferred stock dividend | ( | ) | ( | ) | ||||
| Preferred stock deemed dividend | ||||||||
| Net loss attributed to Streamex Corp. Common Shareholders | ( | ) | ( | ) | ||||
| Net loss per common share, basic and diluted | $ | ) | $ | ) | ||||
| Weighted average number of common shares outstanding, basic and diluted | ||||||||
| Comprehensive (Loss) Income: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Other comprehensive loss | ||||||||
| Change in foreign currency translation adjustments | ( | ) | ||||||
| Total comprehensive loss | ( | ) | ( | ) | ||||
| Comprehensive (loss) income attributable to non-controlling interest | ( | ) | ||||||
| Comprehensive loss attributable to Streamex Corp. | $ | ( | ) | $ | ( | ) | ||
The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements
| 4 |
STREAMEX CORP.
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY
(Unaudited)
(In Thousands, Except Par Value and Share Amounts)
Common stock Shares | Amount | Additional Paid-in- Capital | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) | Non- controlling Interest | Total | ||||||||||||||||||||||
| Balance, December 31, 2025 | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
| Stock based compensation | ||||||||||||||||||||||||||||
| Exercise of warrants | * | |||||||||||||||||||||||||||
| Net proceeds from issuance of common stock in underwritten public offering | ||||||||||||||||||||||||||||
| Conversion of exchangeable shares into common stock | ( | ) | ||||||||||||||||||||||||||
| Conversion of convertible debentures into common stock | ||||||||||||||||||||||||||||
| Issuance of equity to noncontrolling interest holders | - | |||||||||||||||||||||||||||
| Preferred stock dividend | - | ( | ) | ( | ) | |||||||||||||||||||||||
| Other comprehensive loss | - | ( | ) | ( | ) | |||||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||
| Balance, March 31, 2026 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | ||||||||||||||||||
Common stock Shares | Amount | Additional Paid-in- Capital | Accumulated Deficit | Non- controlling Interest | Total | |||||||||||||||||||
| Balance, December 31, 2024 | $ | $ | $ | ( | ) | $ | $ | ( | ) | |||||||||||||||
| Stock based compensation | ||||||||||||||||||||||||
| Exercise of warrants | * | |||||||||||||||||||||||
| Sale of common stock under at-the- market offering, net of transaction costs | ||||||||||||||||||||||||
| Sale of common stock and warrants | ||||||||||||||||||||||||
| Common stock issued to settle accounts payable | * | |||||||||||||||||||||||
| Preferred stock dividend | - | ( | ) | ( | ) | |||||||||||||||||||
| Net (loss) income | - | ( | ) | ( | ) | |||||||||||||||||||
| Balance, March 31, 2025 | $ | $ | $ | ( | ) | $ | $ | |||||||||||||||||
| * |
The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements
| 5 |
STREAMEX CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In Thousands, Except Par Value and Share Amounts)
For the Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to cash used in operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Amortization of debt discount and issuance costs | ||||||||
| Gain on settlement and extinguishment of accounts payable | ||||||||
| Non-cash lease expense | ||||||||
| Realized gain on sale of gold | ( | ) | ||||||
| Realized gain on marketable securities | ( | ) | ||||||
| Change in fair value of marketable securities | ||||||||
| Change in fair value of embedded derivative | ( | ) | ||||||
| Realized loss on extinguishment of convertible debentures | ||||||||
| Realized loss on investment | ||||||||
| Stock-based compensation expense | ||||||||
| Deferred income taxes | ( | ) | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ||||||||
| Lease receivables | ||||||||
| Sales tax receivable | ( | ) | ||||||
| Prepaid expenses and other assets | ( | ) | ( | ) | ||||
| Accounts payable and accrued expenses | ( | ) | ||||||
| Operating lease liabilities | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of marketable securities | ( | ) | ||||||
| Proceeds from the sale of marketable securities | ||||||||
| Proceeds from the sale of non-marketable equity investments | ||||||||
| Proceeds from sale of gold | ||||||||
| Purchase of gold assets | ( | ) | ||||||
| Net cash used in investing activity | ( | ) | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from sale of common stock under at-the-market offerings, net of issuance costs | ||||||||
| Proceeds from sale of common stock and warrants, net of issuance costs | ||||||||
| Repayment of finance obligation | ( | ) | ||||||
| Net proceeds from issuance of common stock in underwritten public offering | ||||||||
| Proceeds from issuance of equity in subsidiary to non-controlling interest holders | ||||||||
| Repayment of convertible debentures | ( | ) | ||||||
| Net cash (used in) provided by financing activities | ( | ) | ||||||
| Effect of exchange rate change on cash | ( | ) | ||||||
| Net (decrease) increase in cash | ( | ) | ||||||
| Cash, beginning of the period | ||||||||
| Cash, end of the period | $ | $ | ||||||
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid during the period for interest | $ | $ | ||||||
| Cash paid during the period for income taxes | $ | $ | ||||||
| Noncash investing and financing activities: | ||||||||
| Common stock issued in settlement of accounts payable | $ | $ | ||||||
| Dividend payable on preferred stock charged to additional paid-in-capital | $ | $ | ||||||
| Conversion of convertible debentures into common stock | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements
| 6 |
STREAMEX CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2026 (Unaudited)
(in thousands, except par value and share amounts)
NOTE 1 – NATURE OF OPERATIONS
Business and organization
Streamex Corp. (the “Company”, “we”, “us” and “our”) is a technology company with two principal lines of business: (i) digital infrastructure focused on the tokenization and exchange of real-world assets and other commodity-linked financial products and (ii) biomedical technology focused on advanced signal acquisition and processing solutions in electrophysiology through our PURE EP™ platform. On May 28, 2025, the Company acquired Streamex Exchange Corporation (“Streamex Exchange”), a software development company based in Vancouver, British Columbia. In connection with this strategic expansion, on September 12, 2025, the Company changed its corporate name from BioSig Technologies, Inc. to Streamex Corp., and effective September 12, 2025, the Company’s common stock began trading on The Nasdaq Capital Market under the ticker symbol “STEX” (formerly “BSGM”).
On May 28, 2025, the Company completed the acquisition of Streamex Exchange pursuant to that certain Share Purchase Agreement dated as of May 23, 2025 (as amended on May 27, 2025, the “Share Purchase Agreement”) by and among the Company, BST Sub ULC, an unlimited liability company organized under the laws of the Province of British Columbia and a wholly owned subsidiary of the Company (“ExchangeCo”), 1540875 B.C. Ltd., a British Columbia company and a wholly owned subsidiary of the Company (“Callco”), the shareholders of Streamex Exchange, and 1540873 B.C. Ltd., as trustee (the “Trustee”) under the exchange rights agreement entered into among the Company, ExchangeCo, Callco, and the Trustee (the “Exchange Rights Agreement”).
The
Company continues to evaluate opportunities for its subsidiaries ViralClear Pharmaceuticals, Inc. (“ViralClear”) and BioSig
AI Sciences, Inc. (“BioSig AI”). As of March 31, 2026 and December 31, 2025, the Company held a majority interest of approximately
During
the three months ended March 31, 2026, the Company, through Streamex Ltd., a Cayman Islands special-purpose entity consolidated as a
variable interest entity, acquired approximately $
NOTE 2 – LIQUIDITY
As
of March 31, 2026, we had working capital of approximately $
During
the three months ended March 31, 2026, the Company strengthened its liquidity position through financing transactions and asset monetization
activities and eliminated its outstanding convertible debt. In January 2026, the Company completed an underwritten public offering generating
net proceeds of approximately $
We expect to continue incurring operating losses and negative cash flows until our products, including the Streamex Exchange’s digital asset infrastructure and PURE EP™ Platform initiatives, achieve sustained commercial success. Although the PURE EP™ Platform is commercially available, revenues to date have not been material, and the timing and extent of future revenues remain uncertain. The Company launched GLDY and began accepting subscriptions; however, revenues to date have not been material. We expect to incur additional costs related to software development, regulatory compliance, and strategic partnerships prior to the commencement of any material revenue-generating activities. The timing and extent of any future revenues will depend on, among other things, continued investor adoption of GLDY, completion of development milestones, regulatory considerations, market conditions, and the successful commercialization of the Streamex Exchange platform and related offerings.
| 7 |
Based on our existing cash and working capital position, management believes that the Company has the ability to continue as a going concern for at least one year from the issuance date of the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. The Company believes it will have sufficient liquidity to meet its anticipated working capital requirements, capital expenditures, and other liquidity needs during that period.
NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2025.
Basis of Consolidation
The accompanying unaudited condensed consolidated financial statements include the accounts of Streamex Corp. and its consolidated subsidiaries, including variable interest entities (“VIEs”) for which the Company is determined to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. Noncontrolling interests represent the portion of equity interests in consolidated subsidiaries not attributable to the Company and are reported as a separate component of stockholders’ equity.
During the three months ended March 31, 2026, the Company determined that it became the primary beneficiary of Streamex Ltd., a Cayman Islands exempted company, under the VIE model in ASC 810, Consolidation. The Company became the primary beneficiary upon the formation and initial capitalization of Streamex Ltd. in February 2026, at which time the Company obtained the power to direct the activities of Streamex Ltd. that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, Streamex Ltd. has been consolidated from the date the Company became the primary beneficiary. See Note 9, Streamex Ltd. (VIE), for additional information.
Use of estimates
The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Changes in circumstances could cause actual results to differ materially from these estimates.
Foreign Currency Translation
The functional currency of the Company’s Canadian subsidiary, ExchangeCo, is the Canadian dollar. Assets and liabilities denominated in Canadian dollars are translated into U.S. dollars at the exchange rate in effect at the balance sheet date, while revenues and expenses are translated at the average exchange rate for the period. Resulting translation adjustments are recorded in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity.
| 8 |
Marketable Securities
The Company’s marketable securities consist of equity securities measured at fair value with changes in fair value recognized in earnings, in accordance with ASC 321, Investments — Equity Securities. Fair value is determined using quoted market prices in active markets (Level 1).
Gold Assets
The Company, through its consolidated variable interest entity Streamex Ltd., holds physical gold bullion. Gold purchased for the purpose of backing GLDY Token obligations is recorded at cost, which includes the purchase price and directly attributable transaction costs, and is classified as “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet. The Company classifies the gold as a non-current asset because the gold is acquired and held to support the long-term GLDY Token program and related leasing activities, and management does not expect to liquidate the gold within the next twelve months. The gold is accounted for as a long-lived tangible asset within the scope of ASC 360. Cost is determined on a specific identification basis. Ongoing storage, insurance, and administrative custody costs are expensed as incurred.
Management evaluates the gold for impairment under ASC 360-10-35 when events or changes in circumstances indicate that the carrying amount may not be recoverable. Such events may include, among other factors, a significant decline in market prices, adverse changes in legal, regulatory, or custodial conditions, or other factors affecting the Company’s ability to access or realize economic benefits from the asset. The Company considers both market-based and asset-specific factors in assessing whether an impairment indicator exists. Once classified as held for sale, the gold is carried at the lower of carrying amount or fair value less cost to sell, with any write-downs recognized in earnings and subsequent increases recognized only to the extent of previously recognized losses. No impairment charges were recorded during the three months ended March 31, 2026.
Gold that has been committed for sale or that management has committed to a plan of sale is reclassified to “Other assets held for sale” and measured at the lower of carrying amount or fair value less costs to sell in accordance with ASC 360.
Concentration of Assets
As
of March 31, 2026, the Company’s consolidated assets totaled $
As
of March 31, 2026, the Company’s cash of $
The Company evaluates geographic concentrations in accordance with ASC 275, Risks and Uncertainties, and considers potential exposure to economic, regulatory, and currency-related risks. While the Canadian-based assets represent a significant portion of consolidated assets, they are not currently subject to material operational, legal, or foreign exchange restrictions. Management believes that the Company is not exposed to heightened risk from geographic concentration, given the nature of the assets, the stability of the Canadian jurisdiction, and the strategic alignment of the Streamex Exchange business with the Company’s broader operations.
The Company computes earnings (loss) per share in accordance with Accounting Standards Codification subtopic 260, Earnings Per Share (“ASC 260”). Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to the Company’s common stockholders by the weighted-average number of shares of common stock outstanding during the period, including exchangeable shares that are economically equivalent to the Company’s common stock.
| 9 |
The Company has outstanding exchangeable shares issued by a consolidated subsidiary that are economically equivalent to the Company’s common stock in all material respects, including rights to dividends and participation in earnings, and are exchangeable on a one-for-one basis into shares of the Company’s common stock at the option of the holders. The exchangeable shares are classified within stockholders’ equity and are included in the weighted-average shares outstanding used in the calculation of basic earnings (loss) per common share because these shares participate equally with the Company’s common stock in undistributed net income (loss).
Diluted earnings per common share is computed by giving effect to all potentially dilutive securities and other contracts to issue common stock using the treasury stock method and the if-converted method, as applicable, in accordance with ASC 260. Potentially dilutive securities may include stock options, warrants, restricted stock units, and other equity awards (treasury stock method), as well as the Company’s convertible preferred stock and convertible debt, including the secured convertible debentures (if-converted method). Under the if-converted method, convertible instruments are assumed to have been converted at the beginning of the period (or at issuance, if later), and related preferred dividends and/or interest expense (net of tax), as applicable, are adjusted in the determination of net income available to common stockholders.
In periods in which the Company reports a net loss, basic and diluted loss per share are the same, as the inclusion of stock options, warrants, restricted stock units, convertible preferred stock, convertible debt and other potentially dilutive securities would be antidilutive. Accordingly, such securities are excluded from the computation of diluted loss per share.
| March 31, | March 31, | |||||||
| 2026 | 2025 | |||||||
| Series C convertible preferred stock | ||||||||
| Options to purchase common stock | ||||||||
| Performance-based restricted stock units | ||||||||
| Warrants to purchase common stock | ||||||||
| Restricted stock units to acquire common stock | ||||||||
| Totals | ||||||||
Recently adopted accounting pronouncements
In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This standard provides all entities with a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the current accounts receivable and current contract assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2025-05 in 2026 and the adoption had no material impact on our unaudited condensed consolidated financial statements.
Recently issued accounting pronouncements not yet adopted
In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 requires disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement and disclosures about selling expenses. As amended by ASU 2025-01, ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating ASU 2024-03 and does not expect it to have a material effect on the Company’s unaudited condensed consolidated financial statements.
| 10 |
In May 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity (“VIE”), which provides clarifying guidance on determining the accounting acquirer in certain transactions involving VIEs. The update aims to improve consistency and comparability in financial reporting. The guidance will be effective for annual periods beginning after December 15, 2026, including interim periods within those annual periods. Early adoption is permitted. Upon adoption, the guidance will be applied prospectively. The Company is currently evaluating the provisions of the amendments and the impact on its future financial statements.
In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, to modernize the accounting guidance for internal-use software costs. The standard removes all references to software development project stages and instead requires capitalization when (i) management has authorized and committed to funding the software project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-06.
NOTE 4 – BUSINESS ACQUISITION
Streamex Exchange Corporation
Transaction Overview
On
The acquisition was effected pursuant to the Share Purchase Agreement dated May 23, 2025, as amended on May 27, 2025, by and among the Company, its wholly-owned subsidiaries ExchangeCo and Callco, the Streamex Exchange Shareholders, and 1540873 B.C. Ltd., as trustee under the Exchange Rights Agreement.
Under the terms of the Share Purchase Agreement, ExchangeCo acquired all of the issued and outstanding shares of Streamex Exchange (the “Purchased Shares”) in exchange for Exchangeable Shares of ExchangeCo, issued at a ratio of Exchangeable Shares per PurchasedShare. The Exchangeable Shares are exchangeable on a one-for-one basis for shares of the Company’s common stock, subject to certain adjustments and conditions described below.
The purpose of the Acquisition was to enhance shareholder value by combining with a privately held operating company and positioning the combined entity for future growth with expansion into digital commodity trading and blockchain-based financial technologies. The acquisition was undertaken to expand the Company’s technology platform into digital commodity trading and blockchain-based financial infrastructure and to obtain the assembled workforce, intellectual property, and regulatory capabilities of Streamex Exchange.
In connection with the transaction, the Company evaluated the accounting under ASC 805, Business Combinations, and ASC 810, Consolidation. The Company concluded the acquired set met the definition of a business. In making this determination, the Company considered the concentration test in ASC 805 and determined that substantially all of the fair value of the gross assets acquired was not concentrated in a single identifiable asset or group of similar identifiable assets. The Company also evaluated whether the acquiree is a variable interest entity (“VIE”) and concluded Streamex Exchange is a VIE because, among other factors, it lacked sufficient equity at risk to finance its activities without additional subordinated financial support and the equity holders, as a group, did not have substantive power to direct the activities that most significantly impact economic performance at the acquisition date.
The Company concluded it is the primary beneficiary because it has both (i) the power to direct the activities that most significantly impact Streamex’s economic performance through governance rights in place at closing and (ii) the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, the transaction is accounted for as a business combination with the Company as the accounting acquirer, and Streamex Exchange has been consolidated in the Company’s financial statements from the acquisition date.
| 11 |
Shareholder Approval and Contingent Features
Initially, the Exchangeable Shares were not exchangeable into more than 19.99% of the Company’s outstanding common stock on a pre-transaction basis, in accordance with Nasdaq listing rules. Following the closing, the Company sought stockholder approval for certain matters related to the transaction, including the issuance of shares of common stock exchangeable for Exchangeable Shares, the issuance of shares underlying the Convertible Debentures, increases to the authorized share count and the 2023 Long-Term Incentive Plan, and amendments to the Company’s Amended and Restated Certificate of Incorporation. At the special meeting of stockholders held on September 5, 2025, all proposals except the issuance of shares exchangeable for Exchangeable Shares (Proposal A) were approved. Proposal A was subsequently approved on November 4, 2025.
Following stockholder approval of Proposal A on November 4, 2025, and subject to the terms of the Exchange Rights Agreement, the holders of Exchangeable Shares are entitled to exchange such shares for an aggregate of shares of the Company’s common stock representing up to 75% of the Company’s fully diluted common stock as of the Share Purchase Agreement date.
Consideration Transferred
The fair value of the consideration transferred was $
On November 4, 2025, the Company received shareholder approval for the issuance of our shares of common stock exchangeable for Exchangeable Shares and one share of Special Voting Preferred Stock in connection with the Share Purchase Agreement. As a result, the conversion cap was removed, and Streamex Exchange shareholders may convert their Exchangeable Shares into the Company’s common stock. Concurrently, the derivative liability associated with the Exchangeable Shares was reclassified to permanent equity. As a result of the reclassification, the Exchangeable Shares are classified as permanent equity and are presented within stockholders’ equity in the consolidated balance sheet. No derivative liability related to the Exchangeable Shares remained outstanding as of March 31, 2026 or December 31, 2025. Although the Exchangeable Shares were reclassified to permanent equity upon stockholder approval on November 4, 2025, the consideration transferred for purposes of the acquisition date purchase price allocation reflects the fair value of the Exchangeable Shares as of May 28, 2025.
In connection with the acquisition of Streamex Exchange, the Company
incurred total acquisition-related costs of $
Purchase Price Allocation
The Company applied the acquisition method of accounting in accordance with ASC 805, Business Combinations (“ASC 805”) and recognized assets acquired and liabilities assumed at their estimated fair value as of the date of acquisition, with the excess purchase consideration recorded to goodwill. During the three months ended March 31, 2026, the Company completed its assessment of the fair values of the assets acquired and liabilities assumed in connection with the acquisition of Streamex Exchange. No measurement period adjustments were recorded during the three months ended March 31, 2026.
The Acquisition was recorded as a business combination based on a valuation of assets acquired and liabilities assumed at their acquisition date fair values using unobservable inputs that are supported by little or no market activity and are significant to their fair value of the assets and liabilities (“Level 3” inputs). Goodwill represents the excess of the purchase price consideration over the valuation of the net assets acquired.
| 12 |
The final allocation of the purchase consideration is as follows:
| Amount Recognized as of the Acquisition Date (In Thousands) | ||||
| Assets acquired | ||||
| Cash | $ | |||
| Due from related party | ||||
| Sales tax receivable | ||||
| Prepaid expenses | ||||
| Trade name | ||||
| Developed technology | ||||
| Legal and compliance framework | ||||
| Goodwill | ||||
| Total assets acquired | $ | |||
| Liabilities assumed | ||||
| Accounts payable and accrued expenses | $ | ( | ) | |
| Deferred tax liability | ( | ) | ||
| Total liabilities assumed | $ | ( | ) | |
| Net assets acquired | ||||
Deferred tax liability
In
connection with the acquisition of Streamex Exchange, the transaction was structured as a stock acquisition for both U.S. and Canadian
tax purposes. No election was made under IRC §338(g); therefore, no step-up in the tax basis of the acquired assets was obtained
in either jurisdiction. The purchase price allocation created taxable temporary differences related to identifiable intangible assets,
resulting in a deferred tax liability of approximately $
Intangible Assets
The Company identified the following finite-lived intangible assets:
| ● | Trade
Name: Valued at $ | |
| ● | Developed Technology | |
| Comprised
of two distinct components, both valued using the multi-period excess earnings method (MPEEM) and amortized over |
| ● | Securitization
Platform: Valued at $ | |
| ● | Blockchain
Integration: Valued at $ |
| ● | Legal
and Compliance Framework: Valued at $ |
| 13 |
Goodwill
Goodwill
of $
NOTE 5 – GOODWILL AND INTANGIBLE ASSETS
Goodwill
The following table shows the changes in the carrying amount of goodwill for the period:
| Goodwill as of December 31, 2025 (1) | $ | |||
| Acquisition | ||||
| Impairment | ||||
| Foreign currency translation adjustment | ( | ) | ||
| Goodwill as of March 31, 2026 | $ |
| 1) |
During the three months ended March 31, 2026, the Company evaluated the existence of any indicators of impairment in accordance with ASC 350, Intangibles—Goodwill and Other. Based on the qualitative assessment performed, management concluded that the combination of factors considered did not result in a triggering event requiring a quantitative impairment test. Based on the assessment, there was no goodwill impairment recognized in the three months ended March 31, 2026.
| 14 |
Intangible Assets
Intangible assets consist of trade name, developed technology, legal and compliance framework, and patents, and are initially recorded at fair value. Long-lived intangible assets are amortized over their estimated useful lives in a method reflecting the pattern in which the economic benefits are consumed or amortized on a straight-line basis if such pattern cannot be reliably determined. The Company evaluates its finite-lived intangible assets for impairment in accordance with ASC 360-10-35 whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. During the three months ended March 31, 2026, the Company evaluated whether any such triggering events existed, including consideration of changes in the business environment, market conditions, and asset utilization. Based on this assessment, management concluded that no triggering events occurred and that the carrying amounts of the Company’s finite-lived intangible assets were recoverable. Accordingly, no impairment charges were recorded for the three months ended March 31, 2026 or 2025.
The following summarizes the Company’s intangible assets as of March 31, 2026 and December 31, 2025:
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Trade name (1) | $ | $ | ||||||
| Developed technology (1) | ||||||||
| Legal and compliance framework (1) | ||||||||
| Patents | ||||||||
| Total | ||||||||
| Foreign currency translation adjustment | ( | ) | ||||||
| Accumulated amortization: | ||||||||
| Trade name | ( | ) | ( | ) | ||||
| Developed technology | ( | ) | ( | ) | ||||
| Legal and compliance framework | ( | ) | ( | ) | ||||
| Patents | ( | ) | ( | ) | ||||
| Total accumulated amortization | ( | ) | ( | ) | ||||
| Intangible assets, net | $ | $ | ||||||
| 1) |
Amortization
expenses for total intangible assets were $
Expected future amortization expense of intangible assets as of March 31, 2026, is as follows:
| Remainder 2026 | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| 2030 | ||||
| Thereafter | ||||
| $ |
| 15 |
NOTE 6 – PROPERTY AND EQUIPMENT
Property and equipment as of March 31, 2026, and December 31, 2025 is summarized as follows:
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Computer equipment | $ | $ | ||||||
| Furniture and fixtures | ||||||||
| Testing/Demo equipment | ||||||||
| Leasehold improvements | ||||||||
| Total | ||||||||
| Less accumulated depreciation | ( | ) | ( | ) | ||||
| Property and equipment, net | $ | $ | ||||||
As of March 31, 2026, the Company evaluated whether any events or changes in circumstances indicated that the carrying amounts of its property and equipment may not be recoverable. Based on this assessment, no impairment indicators were identified and no impairment charges were recorded during the three months ended March 31, 2026 or 2025.
Depreciation
expenses were $
NOTE 7 – MARKETABLE SECURITIES
Exchange-Traded Funds
The
Company’s marketable securities consist of exchange-traded funds (“ETFs”) holding short-term U.S. Treasury securities
and investment-grade corporate debt instruments. As of March 31, 2026, the portfolio was composed of four ETFs: iShares 0-3 Month Treasury
Bond ETF (SGOV), SPDR Portfolio Short-Term Treasury ETF (SPTS), Vanguard Short-Term Treasury Index ETF (VGSH), and Vanguard Short-Term
Corporate Bond ETF (VCSH), each representing approximately
Fair value is determined using quoted market prices in active markets and, accordingly, all marketable securities are classified within Level 1 of the ASC 820 fair value hierarchy.
During
the three months ended March 31, 2026, the Company purchased approximately $
As of December 31, 2025, the Company held no ETF investments.
Empress Royalty Corp.
On December 9, 2025, the Company entered into a share purchase agreement with Terra Capital Natural Resources Fund Pty Ltd to acquire common shares of Empress Royalty Corp. (“Empress”), representing approximately % of Empress’s outstanding common shares. Empress is listed on the TSX Venture Exchange and OTCQX.
As consideration, the Company issued restricted shares of its common stock on December 12, 2025, the date ownership transferred. The investment was initially recognized at $, based on the fair value of Streamex shares issued at $ per share on December 12, 2025. The Company does not have significant influence over Empress.
| 16 |
As
of December 31, 2025, the fair value of the Empress investment was approximately $, with the resulting unrealized loss of $
recognized in earnings during the year ended December 31, 2025. In January 2026, the Company sold all of its shares in Empress Royalty
Corp. for gross proceeds of approximately $
NOTE 8 – GOLD ASSETS
Gold Bullion — Held for Sale (Sold February 2026)
As
of December 31, 2025, the Company held LBMA Good Delivery gold bullion (the “Gold”) on an allocated, physically segregated
basis in secure vaults operated by Brink’s Global Services USA, Inc. (“Brink’s”) and maintained the Gold in a
securities account with Gold Bullion International, LLC (“GBI”). The aggregate carrying value of the Gold as of December
31, 2025 was approximately $
The restricted portion of the Gold and related account rights were pledged as collateral under the Company’s secured financing arrangements, including the Secured Convertible Debenture Purchase Agreement dated July 7, 2025 and the Guaranty and Security Agreement dated November 4, 2025.
Pursuant to the Securities Account Control Agreement dated November 4, 2025, GBI is required to comply with entitlement orders issued by YA II PN, LTD., acting as collateral agent (the “Collateral Agent”), and GBI will not follow Company instructions unless accompanied by the Collateral Agent’s express written consent. Upon receipt of a notice of sole control following an event of default, GBI would terminate the Company’s access to the securities account and take instructions solely from the Collateral Agent as the entitlement holder with respect to the account and property therein.
Pursuant
to the Brink’s Bailee Agreement dated November 4, 2025, Brink’s acts solely as bailee of the Gold, acknowledges no property
interest in the Gold, and any statutory or possessory liens are subordinated to the Collateral Agent’s first-priority security
interest. Brink’s maximum liability amount under its arrangements with GBI is $
No entitlement orders or notices of sole control were issued during the three months ended March 31, 2026.
On
December 29, 2025, management committed to a plan to sell the Gold in connection with the Company’s plan to resolve and repay its
secured convertible debentures. The Company determined that all criteria for classification as held for sale under ASC 360-10-45-9 were
met as of December 29, 2025. Accordingly, as of December 31, 2025, the Gold was classified as held for sale and measured at the lower
of its carrying amount or fair value less cost to sell. Because fair value less cost to sell exceeded the carrying amount,
In
February 2026, the Company transferred approximately $
On
February 5, 2026, the Company completed the sale of the remaining LBMA Good Delivery gold bullion previously classified as held for sale,
with a carrying amount of approximately $
As
of March 31, 2026,
| 17 |
Gold Assets Held at Cost — Streamex Ltd. (VIE)
During
the three months ended March 31, 2026, Streamex Ltd. (the Company’s consolidated VIE) acquired gold bullion consisting of (i) the
approximately $
As of March 31, 2026, the Company evaluated whether any events or changes in circumstances indicated that the carrying amount of its gold assets held at cost may not be recoverable. Based on this assessment, including consideration of gold market prices as of the balance sheet date, management concluded that no triggering events existed and no impairment charges were recorded during the three months ended March 31, 2026. See Note 9 for additional information regarding Streamex Ltd.
NOTE 9 – STREAMEX LTD. (VIE)
Overview
Streamex Ltd. (“Streamex Ltd.” or the “VIE”) is a special-purpose entity organized in the Cayman Islands and formed to purchase and hold physical gold and to issue digital GLDY Tokens designed to provide tokenholders exposure to gold and gold-denominated leasing returns. Streamex Ltd. may also lease its gold holdings to generate gold-denominated yield. The Company is involved with Streamex Ltd. through its governance rights and through its economic interests in GLDY Tokens.
Streamex Ltd. began operations during the three months ended March 31, 2026.
Variable Interest Entity Consideration
The Company evaluated Streamex Ltd. under the variable interest entity (“VIE”) model in ASC 810, Consolidation. A legal entity is a VIE if, among other conditions, the holders of the equity investment at risk, as a group, lack the power, through voting rights or similar rights, to direct the activities that most significantly impact the entity’s economic performance. Streamex Ltd. is considered a VIE because the holders of GLDY Tokens (which represent non-voting participating equity interests) lack substantive voting rights and do not have the power to direct the activities that most significantly impact Streamex Ltd.’s economic performance. Voting control resides with the single voting management share, which controls shareholder-level decisions including the appointment and removal of directors, and day-to-day operating authority has been delegated to GLDY ServiceCo, LLC, a consolidated subsidiary of the Company, pursuant to a services agreement. Because Streamex Ltd. is a VIE, the Company evaluated whether it is the primary beneficiary and therefore required to consolidate Streamex Ltd., as discussed below.
Primary Beneficiary Conclusion and Consolidation
The Company evaluated its involvement with Streamex Ltd. under ASC 810, Consolidation, and concluded it is the primary beneficiary and is required to consolidate Streamex Ltd. Under ASC 810-10-25-38, a reporting entity is the primary beneficiary of a VIE only if it has both (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company concluded both criteria are met as of March 31, 2026 because it has the power to direct the activities that most significantly impact Streamex Ltd.’s economic performance through its control of the VIE’s governance structure (including the voting management share and related decision rights, as applicable) and the servicer arrangement, and has the obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE due to its economic interest in the GLDY Tokens.
| 18 |
As
of March 31, 2026, the Company held approximately
Carrying Amounts of Assets and Liabilities of Consolidated VIE
The following table presents the carrying amounts and balance sheet classifications of the significant assets and liabilities of Streamex Ltd. included in the Company’s unaudited condensed consolidated balance sheet as of March 31, 2026. The assets of Streamex Ltd. are generally restricted and can be used only to settle obligations of Streamex Ltd.
Streamex Ltd. assets and liabilities included in the unaudited condensed consolidated balance sheet as of March 31, 2026:
| Assets | ||||
| Other assets held at cost – gold | $ | |||
| Cash | ||||
| Total assets | $ | |||
| Liabilities | ||||
| Accounts payable and accrued expenses | $ | |||
| Total liabilities | $ | |||
During
the three months ended March 31, 2026, Streamex Ltd. incurred a net loss of approximately $
During
March 2026, two officers of the Company subscribed for GLDY Tokens directly with Streamex Ltd.: (i) the Company’s Chief Investment
Officer, subscribed for approximately $
Lack of Recourse / Restrictions
The assets of Streamex Ltd. are generally not available to satisfy the obligations of the Company or its other subsidiaries, and the creditors and tokenholders of Streamex Ltd. generally do not have recourse to the general credit of the Company beyond the assets of Streamex Ltd., except to the limited extent of intercompany balances eliminated in consolidation. The liabilities recognized as a result of consolidating Streamex Ltd. do not represent additional claims on the Company’s general assets.
Maximum Exposure to Loss / Financial Support
The
Company’s maximum exposure to loss associated with its involvement with Streamex Ltd. as of March 31, 2026 is limited to the carrying
amount of its approximately
| 19 |
Related Party Considerations / Intercompany Eliminations
Streamex Ltd. pays servicing fees to GLDY ServiceCo, LLC, a consolidated subsidiary of the Company, under the applicable servicing arrangement. Because the servicer is a consolidated subsidiary, these servicing fees and related intercompany balances are eliminated in consolidation.
Noncontrolling Interest
As
of March 31, 2026, noncontrolling interests in Streamex Ltd. consisted of (i) the single voting management share held by the VIE’s
director, which carries governance rights but no material economic interest, and (ii) GLDY Tokens held by two officers of the Company
who subscribed as related party investors during March 2026. In aggregate, related party tokenholders held approximately
The
noncontrolling interest attributable to Streamex Ltd. as of March 31, 2026 was approximately $
Ongoing Assessment
The Company reassesses its primary beneficiary conclusion on an ongoing basis in accordance with ASC 810 whenever changes in facts and circumstances occur that could affect the determination of whether either criterion under ASC 810 continues to be met. Changes that could affect the primary beneficiary assessment include, but are not limited to, changes in GLDY Token ownership (including issuance, redemption, or transfer of GLDY Tokens to unrelated third parties that could affect the significance of the Company’s economic exposure to the VIE), modifications of governing documents or fee arrangements, changes in ownership of the management share, or replacement of the affiliated servicer by an unrelated party. As of March 31, 2026, no changes in facts or circumstances have occurred that would alter the Company’s conclusion.
NOTE 10 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable and accrued expenses as of March 31, 2026, and December 31, 2025, consist of the following:
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Accrued accounting and legal | $ | $ | ||||||
| Accrued consulting | ||||||||
| Accrued interest | ||||||||
| Accrued research and development expenses | ||||||||
| Accrued office and other | ||||||||
| Accrued insurance premium financing(1) | ||||||||
| Accrued payroll(2) | ||||||||
| Other accrued expenses | ||||||||
| $ | $ | |||||||
| (1) | ||
| (2) |
| 20 |
NOTE 11 – CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS
On
November 4, 2025 and December 17, 2025, the Company issued two tranches of senior secured convertible debentures to YA II PN, Ltd. (“Yorkville”)
(collectively, the “Convertible Debentures”) with aggregate principal of $
Each
debenture was issued at a purchase price of
The Convertible Debentures were secured by first-priority liens on substantially all assets of the Company and were guaranteed by certain subsidiaries. Upon settlement in February 2026, all related security interests and liens were released.
Conversion Features
Yorkville could convert all or any portion of the outstanding principal and accrued interest into shares of the Company’s common stock at a conversion price equal to the lower of:
(i)
a fixed price of $
(ii) 97% of the lowest daily volume-weighted average price (“VWAP”) during the three trading days immediately preceding conversion, subject to a $ per share floor price, in each case subject to customary anti-dilution adjustments.
Conversions were also subject to a beneficial ownership limitation (generally 4.99%) and an exchange cap tied to Nasdaq rules, unless stockholder approval was obtained or the limitation was otherwise waived pursuant to the debenture terms.
If
fully converted at the $ floor price, the $
Embedded Derivative Liability – Conversion Option
The Company determined that the holder’s optional conversion feature requires bifurcation as an embedded derivative under ASC 815, Derivatives and Hedging, because (i) the economic characteristics of the conversion feature were not clearly and closely related to the host debt instrument and (ii) the conversion feature did not qualify for equity classification due to its variable conversion pricing mechanics, including VWAP-based pricing, floor price provisions, and reset features.
| 21 |
Accordingly, the embedded conversion option was accounted for separately as a derivative liability measured at fair value, with changes in fair value recognized in earnings each reporting period. At issuance, the Company allocated proceeds between the host debt and the embedded derivative based on relative fair value, with the derivative recorded as a liability and a corresponding amount recorded as a debt discount on the host debenture. This debt discount was amortized to interest expense using the effective interest method over the estimated term of the debenture. As of March 31, 2026, the embedded derivative liability was fully settled and no balance remained outstanding. See Note 12, Fair Value Measurements, for information regarding the valuation methodology, significant unobservable inputs, sensitivity considerations, changes in fair value, the tabular presentation of gains and losses on derivative instruments recognized in earnings as required by ASC 815, and the Level 3 rollforward of the embedded derivative liability.
The Company does not designate any derivative instruments as hedging instruments for accounting purposes and does not apply hedge accounting.
Debt Carrying Amount and Interest Expense
As
of March 31, 2026, the carrying value of the Convertible Debentures, net of unamortized original issue discount, debt issuance costs,
and bifurcation-related discounts, was $
Interest
expense recognized for the three months ended March 31, 2026 includes stated coupon interest and amortization of debt discounts and issuance
costs under the effective interest method. For the three months ended March 31, 2026, the Company recognized total interest expense of
approximately $
The
effective interest rate on the Convertible Debentures substantially exceeded the
Outstanding Principal
As
of March 31, 2026, and December 31, 2025, the outstanding principal balance of the Convertible Debentures was $
Settlement and Extinguishment
On January 22, 2026, the Company delivered an irrevocable optional prepayment notice with respect to the Convertible Debentures.
On
February 6, 2026, the Company settled the Convertible Debentures, which had an aggregate outstanding principal of $
| 22 |
The
remaining unamortized debt discounts of $
In connection with the settlement, the Company recognized the following:
| Loss on extinguishment of convertible debentures — prepayment premium | $ | ( | ) | |
| Gain on derecognition of embedded derivative at settlement | ||||
| Realized loss on extinguishment of convertible debentures | $ | ( | ) |
Upon payment in full, the Convertible Debentures were satisfied and terminated, and all related security interests and liens were released.
We also entered into a SEPA with Yorkville that provided the Company with the right, but not the obligation, to sell shares of common stock during the commitment period. We terminated the SEPA effective January 29, 2026, and did not sell any shares under the SEPA.
Cross-references to related disclosures
Derivative-related qualitative, quantitative, and tabular disclosures are included in more than one note to the unaudited condensed consolidated financial statements. Accordingly, the Company provides the following cross-references:
| ● | Note 4 — Business Acquisition (Exchangeable Shares issued as consideration and related acquisition disclosures) | |
| ● | Note 12 — Fair Value Measurements (fair value hierarchy and valuation inputs for Level 3 instruments, as applicable) | |
| ● | Note 13 — Stockholders’ Equity (Exchangeable Shares and Special Voting Preferred Stock; reclassification to equity) | |
| ● | Note 14 — Options, Restricted Stock Units and Warrants (warrant terms and Fundamental Transaction cash settlement / repurchase activity) |
NOTE 12 – FAIR VALUE MEASUREMENTS
The Company measures certain financial instruments at fair value on a recurring basis in accordance with ASC 820, Fair Value Measurement. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
Assets and liabilities that are measured at fair value on a nonrecurring basis relate primarily to tangible property and equipment, goodwill and other intangible assets, which are remeasured when the derived fair value is below carrying value in the consolidated balance sheets. For these assets, the Company does not periodically adjust carrying value to fair value except in the event of impairment. If it is determined that impairment has occurred, the carrying value of the asset is reduced to fair value and the difference is included in impairments and other charges, net in the consolidated statements of operations.
| 23 |
Nonrecurring Level 3 Fair Value Measurements
Assets that are measured at fair value and classified as level 3 on a nonrecurring basis are as follows:
| Description | May 28, 2025 | |||
| Trade name | $ | |||
| Developed technology | $ | |||
| Legal and compliance framework | $ | |||
| Goodwill | $ | |||
All these assets were measured at the acquisition dates in conjunction with the Streamex Exchange acquisition. See Note 4, Business Acquisition, for additional information regarding the purchase price allocation and valuation methodologies.
Derivative Liabilities – Recurring Fair Value Measurements (Embedded Conversion Options)
The embedded conversion options associated with the Company’s secured convertible debentures were bifurcated and accounted for as derivative liabilities under ASC 815. The derivative liabilities were measured at fair value upon issuance of each debenture tranche (November 4, 2025 and December 17, 2025) and subsequently remeasured at fair value on a recurring basis through settlement on February 6, 2026. See Note 11, Convertible Debentures and Related Derivative Instruments, for information regarding the terms of the Convertible Debentures, the bifurcation analysis, settlement mechanics, and extinguishment accounting.
The Company estimated the fair value of the embedded conversion options using a Monte Carlo simulation model within a “with-and-without” framework, which isolates the value of the holder’s conversion option by comparing the fair value of the debentures with and without the embedded conversion feature. The Monte Carlo model was designed to capture the path-dependent and non-linear features of the conversion option, including variable conversion pricing, contractual floor prices, amortization mechanics, optional prepayment features, and management’s expectations regarding conversion and repayment behavior. Because the valuation utilized significant unobservable inputs, the derivative liabilities were classified as Level 3 within the fair value hierarchy.
Prior to settlement on February 6, 2026, the embedded conversion derivative was valued using a Monte Carlo simulation model incorporating the following significant unobservable inputs (Level 3):
| 2/6/2026 | 12/31/2025 | |||||||
| Unobservable / key assumption | Remeasurement | Remeasurement | ||||||
| Common stock price | $ | $ | ||||||
| Indicated conversion price | $ | $ | ||||||
| Floor price | $ | $ | ||||||
| Prepayment probability | % | % | ||||||
| Prepayment premium | % | % | ||||||
| Registration probability | % | % | ||||||
The February 6, 2026, valuation incorporated management’s assessment that optional prepayment was the most likely outcome and weighted prepayment and non-prepayment scenarios accordingly. Registration-dependent conversion scenarios were assigned a zero probability, as registration effectiveness was not expected.
The fair value of the derivative liabilities is most sensitive to changes in the Company’s stock price, expected volatility, and assumptions regarding the timing and likelihood of prepayment. An increase in expected volatility or stock price would generally increase the fair value of the derivative liability, while an increase in the probability of early prepayment would generally decrease the fair value. Due to the path-dependent nature of the valuation, quantitative sensitivity analyses are not presented.
During
the three months ended March 31, 2026, the Company recognized a gain of $
| 24 |
The following table presents the impact of the Company’s derivative instruments on earnings for the three months ended March 31, 2026:
| Amount | ||||
| Change in fair value of embedded derivative | $ | |||
Rollforward of Level 3 Recurring Fair Value Measurements – Embedded Derivative Liabilities:
| Amount | ||||
| Balance as of December 31, 2025 | $ | |||
| Change in fair value | ( | ) | ||
| Settlements | ( | ) | ||
| Balance as of March 31, 2026 | $ | |||
Investment in Empress Royalty Corp.
The Company’s investment in Empress Royalty Corp. is measured at fair value each reporting period based on quoted market prices in active markets. This represents a Level 1 measurement within the fair value hierarchy. The fair value is based on quoted prices on the TSX Venture Exchange (principal market), translated into U.S. dollars using the spot exchange rate at the measurement date.
In
January 2026, the Company sold all of its shares in Empress Royalty Corp. for gross proceeds of approximately $
Exchange-Traded Funds
The Company’s investments in exchange-traded funds (“ETFs”) holding short-term U.S. Treasury securities and investment-grade corporate debt instruments are measured at fair value each reporting period based on quoted market prices in active markets. This represents a Level 1 measurement within the fair value hierarchy.
Recurring Fair Value Measurements
The following table presents information about the Company’s financial instruments measured at fair value on a recurring basis as of March 31, 2026 (in thousands):
| Description | Level | March 31, 2026 | December 31, 2025 | |||||||||
| Embedded derivative liabilities – Yorkville Debentures | 3 | $ | $ | |||||||||
| Marketable securities | 1 | $ | $ | |||||||||
NOTE 13 – STOCKHOLDERS’ EQUITY
Preferred stock
The Company is authorized to issue shares of $ par value preferred stock. As of March 31, 2026 and December 31, 2025, the Company has designated shares of Series A preferred stock, shares of Series B preferred stock, shares of Series C Preferred Stock, shares of Series D Preferred Stock, shares of Series E Preferred Stock, shares of Series F Preferred Stock and 1 Special Voting Preferred Stock. As of March 31, 2026 and December 31, 2025, there were no issued or outstanding shares of Series A, Series B, Series D, Series E and Series F preferred stock.
| 25 |
Special Voting Preferred Stock
In connection with the issuance of Exchangeable Shares, the Company designated one share of Special Voting Preferred Stock, par value $ per share. One share of Special Voting Preferred Stock was issued and outstanding as of March 31, 2026, and December 31, 2025.
The Special Voting Preferred Stock was issued to a trustee and does not have any economic rights, including rights to dividends or participation in liquidation, other than a nominal liquidation preference of $. The Special Voting Preferred Stock is not convertible into common stock.
The sole purpose of the Special Voting Preferred Stock is to provide voting rights to holders of Exchangeable Shares on an equivalent basis with holders of the Company’s common stock. The holder of the Special Voting Preferred Stock is entitled to cast a number of votes equal to the aggregate number of votes that the holders of Exchangeable Shares would be entitled to cast if such Exchangeable Shares were exchanged for shares of the Company’s common stock, in accordance with the Exchange Rights Agreement.
The voting rights associated with the Special Voting Preferred Stock terminate automatically upon the exchange or cancellation of all outstanding Exchangeable Shares, at which time the Special Voting Preferred Stock is automatically cancelled for no consideration.
Series C Preferred Stock
Series
C Preferred Stock (“Series C”) issued and outstanding totaled shares as of March 31, 2026, and December 31, 2025. As
of March 31, 2026, and December 31, 2025, the Company has accrued $
Each
share of Series C is convertible at the holder’s option into shares of common stock at a conversion price of $
Common stock
The Company is authorized to issue shares of $ par value common stock. As of March 31, 2026, and December 31, 2025, the Company had and shares issued and outstanding, respectively.
Exchangeable Shares
During the three months ended March 31, 2026, holders of Exchangeable Shares converted a total of Exchangeable Shares into an equal number of shares of the Company’s common stock. As of March 31, 2026 and December 31, 2025, the Company had and Exchangeable Shares outstanding, respectively, each of which is exchangeable on a one-for-one basis for a share of the Company’s common stock, subject to the terms of the exchange agreement.
Sale of Common Stock.
On
January 22, 2026, the Company entered into an underwriting agreement with Needham & Company, LLC, as representative of the several
underwriters, in connection with an underwritten public offering of the Company’s common stock. The Company issued shares
of common stock at a public offering price of $ per share. The underwriters fully exercised their over-allotment option, resulting
in the issuance of an additional
| 26 |
ATM Sales Agreement 2024
As
of March 31, 2026, the Company had approximately $
Equity Line of Credit
As of March 31, 2026, the Company had approximately $ of remaining capacity under its Equity Subscription Agreement with Lind Global Fund III, LP, dated February 28, 2025, subject to the filing and effectiveness of a registration statement. No advances have been made under the Subscription Agreement as of March 31, 2026.
Streamex Corp.
2023 Long-Term Incentive Plan
Stockholders
approved the Third Amendment to the Company’s 2023 Long-Term Incentive Plan (the “Incentive Plan Amendment”) on September
5, 2025, increasing the total number of shares authorized for issuance under the plan by shares, from
Stockholders
approved the Fourth Amendment to the Company’s 2023 Long-Term Incentive Plan on December 30, 2025, increasing the total number
of shares authorized for issuance under the plan by shares, from
As of March 31, 2026, there were shares available under the 2023 Long-Term Incentive Plan.
Options
Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from historical stock prices of the Company. The Company accounts for the expected life of options based on the contractual life of options for non-employees.
For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.
| Options Outstanding | Options Exercisable | ||||||||||||
| Exercise | Number of | Weighted Average Remaining Life | Exercisable Number of | ||||||||||
| Price | Options | In Years | Options | ||||||||||
| $ | Under | ||||||||||||
| $ | - | ||||||||||||
| $ | - | ||||||||||||
| $ | - | ||||||||||||
| 27 |
| Shares | Weighted-Average Exercise Price | Weighted-Average Remaining Contractual Term | Aggregate Intrinsic Value | |||||||||||||
| Outstanding at January 1, 2026 | $ | $ | ||||||||||||||
| Issued | $ | |||||||||||||||
| Forfeited/expired | ( | ) | $ | |||||||||||||
| Outstanding at March 31, 2026 | $ | $ | ||||||||||||||
| Exercisable at March 31, 2026 | $ | $ | ||||||||||||||
The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on options with an exercise price less than the stock price of the Company of $ as of March 31, 2026, which would have been received by the option holders had those option holders exercised their options as of that date.
During the three months ended March 31, 2026, the Company granted an aggregate of options to purchase the Company’s common stock at a weighted average exercise price of $ per share for a term of . The options vested immediately upon grant and the full grant-date fair value of approximately $ was recognized as stock-based compensation expense during the three months ended March 31, 2026.
Stock based compensation expense related to stock options recognized during the three months ended March 31, 2026 and 2025, was $ and $, respectively, which is presented within general and administrative expenses in the unaudited Condensed Consolidated Statements of Operations. As of March 31, 2026, there was unrecognized compensation expense related to stock options.
On May 23, 2025, in connection with the Company’s acquisition of Streamex Exchange, the Company entered into an amendment to the Executive Employment Agreement with the Company’s former Chief Executive Officer and Chairman of the Board. Pursuant to the amendment, all previously granted equity awards to the former Chief Executive Officer and Chairman of the Board including vested and unvested stock options were accelerated and deemed fully vested and nonforfeitable as of May 28, 2025. In addition, the post-resignation exercise period for all vested options was extended to the later of the original expiration date or 36 months following the transaction closing.
| Assumption | Value | |||
| Weighted average grant date fair value | $ | |||
| Expected volatility | % | |||
| Risk-free interest rate | % | |||
| Expected dividend yield | % | |||
| Expected Term (in years) | ||||
| 28 |
Warrants
| Exercise Price | Number of Warrants | Expiration Date | ||||||
| $ | ||||||||
During
the three months ended March 31, 2026, the Company issued shares of its common stock upon cashless exercise of
A summary of the warrant activity for three months ended March 31, 2026 is as follows:
| Shares | Weighted-Average Exercise Price | Weighted-Average Remaining Contractual Term | Aggregate Intrinsic Value | |||||||||||||
| Outstanding at January 1, 2026 | $ | $ | ||||||||||||||
| Issued | - | - | ||||||||||||||
| Forfeited/expired | - | - | - | |||||||||||||
| Exercised | ( | ) | - | - | ||||||||||||
| Outstanding at March 31, 2026 | $ | $ | ||||||||||||||
| Vested and expected to vest at March 31, 2026 | $ | $ | ||||||||||||||
| Exercisable at March 31, 2026 | $ | $ | ||||||||||||||
The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the company’s stock price of $ as of March 31, 2026, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.
Restricted Stock Units
| Number of Shares | Weighted-Average Grant Date Fair Value Per Share | |||||||
| Restricted shares issued as of January 1, 2026 | $ | |||||||
| Granted | $ | |||||||
| Vested and issued | ( | ) | $ | |||||
| Forfeited | ( | ) | $ | |||||
| Total | $ | |||||||
| Comprised of: | ||||||||
| Vested restricted shares as of March 31, 2026 | $ | |||||||
| Unvested restricted shares as of March 31, 2026 | $ | |||||||
| 29 |
Stock based compensation expense related to RSU grants was $ and $for the three months ended March 31, 2026 and 2025, respectively, which is included in general and administrative expenses in the unaudited condensed consolidated statements of operations. As of March 31, 2026, total unrecognized stock-based compensation cost related to unvested RSUs was approximately $, which is expected to be recognized over a weighted-average period of approximately years.
The following table summarizes the terms of individual RSU grants issued during the three months ended March 31, 2026 that were subject to vesting conditions extending beyond the grant date:
| Grant Date | Recipient | RSUs Granted | Vesting Terms | GDFV1 | ||||||||
| 1/1/2026 | Third-party consultant | $ | ||||||||||
| 1/8/2026 | Interim Executive Chairman | $ | ||||||||||
| 1/8/2026 | Chief Executive Officer | $ | ||||||||||
| 1/27/2026 | Third-party consultant | $ | ||||||||||
| 2/1/2026 | Third-party consultant | $ | ||||||||||
| 3/3/2026 | Third-party consultant | $ | ||||||||||
| 3/16/2026 | Third-party consultant | $ | ||||||||||
| 3/16/2026 | Chief Financial Officer | $ | ||||||||||
| $ | ||||||||||||
| (1) |
The table above includes only RSU grants issued during the three months ended March 31, 2026 that were subject to vesting conditions extending beyond the grant date. During the same period, the Company also granted an aggregate of RSUs that vested immediately upon grant and are therefore excluded from this table. The total RSUs granted during the three months ended March 31, 2026 were , as reflected in the RSU activity table above.
Performance-Based Restricted Stock Units
During the three months ended March 31, 2026, the Company granted performance-vesting restricted stock units (“PSUs”) to certain consultants. The PSUs represent the right to receive shares of the Company’s common stock upon the achievement of specified performance conditions or market conditions, and satisfaction of service requirements, subject to certification by the Company’s Board of Directors or its Compensation Committee (the “Committee”). The PSUs are equity-classified awards and settle solely in shares of the Company’s common stock. No cash settlement alternative exists.
Stock Price-Based PSUs
On February 1, 2026, the Company granted PSUs to a third-party consultant, under a consulting agreement effective February 1, 2026. The PSUs vest in five tranches upon the achievement of specified stock price milestones, measured by the closing price of the Company’s common stock on a U.S. national securities exchange, as follows: shares at $; shares at $; shares at $; shares at $; and shares at $. Each milestone is certified by the Committee in good faith, and the consultant must be providing continuous service through the certification date. All unvested PSUs are forfeited immediately upon cessation of service. The stock price milestones and shares issuable per tranche are subject to equitable adjustment for stock splits, reverse stock splits, and similar events under the Company’s 2023 Long-Term Incentive Plan.
| 30 |
The stock price targets represent market conditions because they relate to the achievement of specified stock prices of the Company’s equity instruments. In accordance with ASC 718, the effect of the market conditions is reflected in the estimate of the grant-date fair value of the awards. The Company estimated the grant-date fair value of each tranche using a Monte Carlo simulation model, which incorporated the following significant assumptions:
| Assumption | Value | |||
| Grant-date stock price | $ | |||
| Stock price milestones | $ – $ | |||
| Expected volatility | ||||
| Risk-free interest rate | ||||
| Expected dividend yield | ||||
| Derived service periods (range) | – years | |||
The following table summarizes the grant-date fair value by tranche (in thousands, except per unit data and units):
| Tranche | Milestone | GDFV1/Unit | Units | Agg FV2 | DSP3 (yrs) | Q1 2026 Expense | ||||||||||||||||||
| 1 | $ | $ | $ | $ | ||||||||||||||||||||
| 2 | $ | $ | $ | $ | ||||||||||||||||||||
| 3 | $ | $ | $ | $ | ||||||||||||||||||||
| 4 | $ | $ | $ | $ | ||||||||||||||||||||
| 5 | $ | $ | $ | $ | ||||||||||||||||||||
| $ | $ | |||||||||||||||||||||||
| (1) | ||
| (2) | ||
| (3) |
The aggregate grant-date fair value of the stock price-based PSUs was approximately $. In accordance with ASC 718-10-25-8, compensation cost is recognized on a straight-line basis over the derived service period for each tranche, regardless of whether the stock price milestones are ultimately achieved. Previously recognized compensation cost is not reversed if a market condition is not satisfied, provided that all necessary service has been rendered.
During
the three months ended March 31, 2026, the Company recognized stock-based compensation expense of approximately $ related to the stock
price-based PSUs, which is included in general and administrative expenses in the unaudited condensed consolidated statements of operations.
As of March 31, 2026, unrecognized compensation cost related to the stock price-based PSUs was approximately $
The consultant is also entitled to time-based RSUs ( vesting on the effective date and vesting quarterly over 12 months), which are separately disclosed in the RSU section above.
| 31 |
AUM-Based PSUs
On
March 16, 2026, the Company granted up to PSUs to a third-party consultant, vesting upon the achievement of assets under management
(“AUM”) milestones related to the Company’s rare earth elements (“REE”) Fund (a planned commodity-linked
investment product): (
These
PSUs contain performance conditions under ASC 718. The grant-date fair value per unit was determined based on the closing price of the
Company’s common stock of $
Summary of PSU Awards
As of March 31, 2026, total stock-based compensation expense recognized for PSU awards during the three months ended March 31, 2026 was approximately $, consisting entirely of expense related to the stock price-based PSUs. For the AUM-based PSUs, management assessed the probability of achieving each performance condition on a tranche-by-tranche basis and concluded that no condition met the “probable” threshold under ASC 718; accordingly, no expense was recognized.
Total
unrecognized compensation cost related to outstanding PSUs was approximately $
The Company accounts for forfeitures as they occur. No forfeitures of PSUs were recognized during the three months ended March 31, 2026.
| PSUs – Stock Price | PSUs - AUM | Total PSUs | ||||||||||
| Nonvested as of December 31, 2025 | ||||||||||||
| Granted | ||||||||||||
| Vested and issued | ||||||||||||
| Forfeited | ||||||||||||
| Nonvested as of March 31, 2026 | ||||||||||||
| 32 |
The table above excludes (i) performance-based restricted stock units tied to Organic Gross Revenue Growth targets, under which certain consultants may earn additional units annually based on achievement of annual revenue growth targets established and certified by the Compensation Committee, as the number of units issuable is not determinable until the applicable targets are set, and (ii) PSU grants to four third-party consultants, involving an aggregate of up to approximately 910,000 units tied to cumulative gross revenue and token-related performance milestones, that have not been approved by the Board of Directors or the Compensation Committee as of March 31, 2026 and are therefore not considered granted under ASC 718.
ViralClear Pharmaceuticals, Inc.
2019 Long-Term Incentive Plan
There are shares remaining available for future issuance of awards under the terms of the ViralClear Plan.
Warrants (ViralClear)
A summary of the warrant activity for three months ended March 31, 2026 is as follows:
| Weighted-Average | ||||||||||||
| Remaining | ||||||||||||
| Weighted-Average | Contractual | |||||||||||
| Shares | Exercise Price | Term | ||||||||||
| Outstanding at January 1, 2026 | $ | |||||||||||
| Forfeited/expired | - | |||||||||||
| Outstanding at March 31, 2026 | $ | |||||||||||
| Exercisable at March 31, 2026 | $ | |||||||||||
The following table presents information related to warrants (ViralClear) at March 31, 2026:
| Exercise | Number | Expiration | ||||||||
| Price | Outstanding | Date | ||||||||
| $ | ||||||||||
Restricted stock units (ViralClear)
The following table summarizes the restricted stock activity for the three months ended March 31, 2026:
| Restricted shares outstanding at January 1, 2026: | ||||
| Forfeited | ||||
| Total restricted shares outstanding at March 31, 2026: | ||||
| Comprised of: | ||||
| Vested restricted shares as of March 31, 2026 | ||||
| Unvested restricted shares as of March 31, 2026 | ||||
| Total |
BioSig AI Sciences, Inc.
Warrants (BioSig AI)
The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at March 31, 2026:
| Exercise | Number | Expiration | ||||||||
| Price | Outstanding | Date | ||||||||
| $ | June-July 2028 | |||||||||
| 33 |
NOTE 15 – NON-CONTROLLING INTEREST
As
of March 31, 2026 and December 31, 2025, the Company had a majority interest in ViralClear of approximately
A reconciliation of ViralClear Pharmaceuticals, Inc., BioSig AI Sciences, Inc. and Streamex Ltd. non-controlling loss attributable to the Company:
Net loss attributable to the non-controlling interest for the three months ended March 31, 2026:
| ViralClear Pharmaceuticals, Inc. | BioSig AI Sciences, Inc. | Streamex Ltd | Total | |||||||||||||
| Net Income (loss) | $ | * | $ | $ | ( | ) | $ | ( | ) | |||||||
| Noncontrolling interest’s weighted-average ownership percentage | % | % | % | % | ||||||||||||
| Net income (loss) attributable to non-controlling interest | $ | * | $ | $ | ( | ) | $ | ( | ) | |||||||
Net loss attributable to the non-controlling interest for the three months ended March 31, 2025:
| ViralClear Pharmaceuticals, Inc. | BioSig AI Sciences, Inc. | Streamex Ltd | Total | |||||||||||||
| Net loss | $ | * | $ | $ | $ | |||||||||||
| Noncontrolling interest’s weighted-average ownership percentage | % | % | % | % | ||||||||||||
| Net loss attributable to non-controlling interest | $ | * | $ | $ | $ | |||||||||||
| * |
The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2026:
| ViralClear Pharmaceuticals, Inc. | BioSig AI Sciences, Inc. | Streamex Ltd | Total | |||||||||||||
| Balance, January 1, 2026 | $ | ( | ) | $ | $ | $ | ||||||||||
| Issuance of equity to noncontrolling interest holders | ||||||||||||||||
| Net income (loss) attributable to non-controlling interest | ( | ) | ( | ) | ||||||||||||
| Balance, March 31, 2026 | $ | ( | ) | $ | $ | $ | ||||||||||
The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2025:
| ViralClear Pharmaceuticals, Inc. | BioSig AI Sciences, Inc. | Streamex Ltd | Total | |||||||||||||
| Balance, January 1, 2025 | $ | ( | ) | $ | $ | $ | ||||||||||
| Net income (loss) attributable to non-controlling interest | ||||||||||||||||
| Balance, March 31, 2025 | $ | ( | ) | $ | $ | $ | ||||||||||
| 34 |
NOTE 16 — COMMITMENTS AND CONTINGENCIES
Tokenized Yield Partnership Agreement
Overview
On September 8, 2025, the Company entered into a Tokenized Yield Partnership Agreement (the “Token Agreement”) with Monetary Metals & Co. (“MM”), a Delaware corporation, establishing an exclusive, multi-year strategic partnership to design, launch, and distribute blockchain-based financial products that tokenize the yield generated from MM’s precious-metal lease and bond programs. The Token Agreement commenced on September 8, 2025 and continues for an initial term of three years, subject to automatic one-year renewal periods unless terminated in accordance with its terms.
For additional information regarding the gold assets held by Streamex Ltd. and the related VIE disclosures, see Notes 8 and 9.
Exclusivity and Performance Conditions
For at least three years, MM agreed not to engage with any other party to tokenize the yield or other financial attributes of its precious-metal lease or bond products, and the Company agreed not to partner with any third party to tokenize yield derived from precious-metal leases, in each case subject to specified volume-based performance conditions. To maintain exclusivity, the Company must supply at least 10% of the total leased ounces presented by MM each quarter that meet defined criteria, including minimum insurance standards, a net yield of at least 3% per annum after origination fees, and compliance with restrictions on counterparties and jurisdictions. Failure to meet these thresholds, after a 90-day cure period, results in loss of exclusivity but does not obligate the Company to commit capital or continue participation.
Consulting Services Agreement
On
February 4, 2026, the Company entered into a consulting agreement with an independent third party to provide advisory and capital markets
related services in connection with the Company’s GLDY Token program. The agreement has an initial term of six months and provides
for a fixed consulting fee of $
Litigation
We may be subject at times to other legal proceedings and claims, which arise in the ordinary course of our business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.
In November 2025, a former advisor filed a Notice of Civil Claim in the Supreme Court of British Columbia against the Company, its wholly owned subsidiary Streamex Exchange Corporation, and certain current officers and directors. The claim alleges, among other things, breach of contract, unjust enrichment, and civil conspiracy in connection with alleged agreements relating to equity interests in Streamex Exchange Corporation prior to the Company’s acquisition of that entity. The plaintiff seeks, among other relief, specific performance, equitable compensation, and damages.
The Company disputes the claims and intends to defend the matter vigorously. As of March 31, 2026, no liability has been recorded in the unaudited condensed consolidated financial statements related to this matter, as management, after consultation with legal counsel, believes that a loss is not probable. The matter is in a preliminary stage and, as a result, the Company is unable to reasonably estimate the possible loss or range of loss, if any, associated with this matter at this time.
| 35 |
NOTE 17 – SEGMENT REPORTING
Chief Operating Decision Maker (CODM) and Segment Evaluation
On May 28, 2025, in connection with the acquisition of Streamex Exchange, the Company appointed Henry McPhie, former co-founder and CEO of Streamex Exchange, as its new Chief Executive Officer and a member of the Board of Directors. As a result of this leadership change, Mr. McPhie was designated as the Company’s new Chief Operating Decision Maker (“CODM”), replacing Anthony Amato, the Company’s former CEO and director.
Following this change, the Company re-evaluated its operating and reportable segments based on the internal financial information reviewed by the CODM for purposes of performance assessment and resource allocation. Although the acquisition of Streamex Exchange introduced a new line of business focused on digital asset infrastructure, the CODM has not yet begun reviewing Streamex Exchange’s operating results separately for purposes of performance assessment or resource allocation. As of March 31, 2026, the CODM continues to evaluate the Company’s financial performance on a consolidated basis, and the internal reporting structure has not been modified to reflect discrete segment-level financial information.
Management believes that a transitional period is appropriate given the timing of the acquisition, the pre-revenue status of Streamex Exchange, and the pending financing and shareholder approvals necessary to operationalize the Streamex Exchange platform. Accordingly, the Company has concluded that no change in reportable segments has occurred as of March 31, 2026. The Company will continue to monitor the CODM’s review practices and internal reporting structure and will update its segment disclosures in future periods if and when discrete financial information is regularly reviewed at the segment level.
In accordance with ASC 280-10-50-34, if a change in reportable segments occurs in a future period, the Company will recast prior-period segment disclosures retrospectively to reflect the new segment structure.
Basis of Segmentation
The
Company’s CODM evaluates financial performance and allocates resources on a consolidated basis. The Company manages its operations
as
| ● | Assesses performance against budgeted targets; | |
| ● | Forecasts future financial results; | |
| ● | Makes strategic and operational decisions; | |
| ● | Allocates resources across the organization. |
Accordingly, the Company has determined that it operates as one reportable and operating segment as of March 31, 2026.
Management continues to evaluate whether the Streamex Exchange business may become a separate reportable segment in future periods, depending on the scale and financial significance, and the CODM’s review of discrete operating results.
Segment Performance Measures
The primary measure used by the CODM to assess performance is consolidated net loss, which is reviewed in conjunction with other consolidated financial metrics. The CODM also evaluates actual results against budgeted amounts and considers consolidated operating results in making decisions about research and development investments and other strategic initiatives.
Segment assets are not separately reported to or reviewed by the CODM. Therefore, the Company does not disclose segment asset information. All assets are managed on a consolidated basis and are reported in the Company’s unaudited condensed consolidated balance sheets.
The Company does not currently disclose geographic revenue or customer concentration by segment, as such information is not reviewed by the CODM. However, this will be reassessed as operations evolve.
| 36 |
Revenue and Expense Information
Information concerning the operations of the Company’s reportable segments is as follows:
| For the Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Revenues | $ | $ | ||||||
| Less Segment expenses: | ||||||||
| Research and development | ||||||||
| General and administrative | ||||||||
| General and administrative - stock-based compensation expenses | ||||||||
| Depreciation and amortization | ||||||||
| Total operating and segment expense | ( | ) | ( | ) | ||||
| Plus: | ||||||||
| Interest expense, net | ( | ) | ||||||
| Realized gain on sale of gold | ||||||||
| Realized gain on marketable securities | ||||||||
| Change in fair value of marketable securities | ( | ) | ||||||
| Change in fair value of embedded derivative | ||||||||
| Realized loss on extinguishment of convertible debenture | ( | ) | ||||||
| Realized loss on investment | ( | ) | ||||||
| Gain on settlement and forgiveness of debt | ||||||||
| Other income (expense), net | ( | ) | ||||||
| Total other income (expense) | ( | ) | ||||||
| Income taxes (benefit) | ( | ) | ||||||
| Segment Net Loss | $ | ( | ) | $ | ( | ) | ||
| Non-controlling interest | ( | ) | ||||||
| Net loss attributable to Streamex Corp. | $ | ( | ) | $ | ( | ) | ||
NOTE 18– RELATED PARTY TRANSACTIONS
Accounts
payable and accrued expenses as of March 31, 2026 include $
During
the three months ended March 31, 2026, two officers of the Company subscribed for GLDY Tokens issued by Streamex Ltd. (the Company’s
consolidated VIE): (i) the Company’s Chief Investment Officer, subscribed for approximately $200 of GLDY Tokens, and (ii) the Company’s
General Counsel, subscribed for approximately $
| 37 |
NOTE 19 – SUBSEQUENT EVENTS
The Company has evaluated subsequent events from the balance sheet date through the date on which these unaudited condensed financial statements were issued. Other than as described in the notes below, the Company did not have any material subsequent events that impacted its unaudited condensed financial statements or disclosures.
GLDY Dividend
Appointment of Director and Equity Awards
On April 28, 2026, the Board appointed the Company’s Chief Investment Officer (“CIO”), to serve as a non-independent director of the Board for a term expiring at the Company’s 2026 annual meeting of stockholders or until his successor is duly elected and qualified, or until the earlier of his death, resignation or removal.
In connection with the CIO’s amended employment agreement effective April 6, 2026, the Board granted the CIO RSUs and a special incentive award of RSUs. Both awards vest in sixteen equal quarterly installments commencing July 1, 2026, subject to continued service, and become fully vested upon a protected termination, a change in control, or the termination.
Amended Employment Agreements and Equity Awards
On May 1, 2026, the Company entered into amended and restated employment agreements with the Company’s Chief Executive Officer (“CEO”) and the Company’s Interim Executive Chairman (“Interim Chairman”).
In connection with the amended agreements, the Board granted each of the CEO and Interim Chairman PSUs for shares of the Company’s common stock, divided into five equal tranches of shares each. Each tranche vests upon the Company’s cumulative sales of GLDY reaching the following milestones: (i) $; (ii) $; (iii) $; (iv) $; and (v) $. Cumulative GLDY sales are measured in good faith by the Company and certified by the Compensation Committee. Vesting is subject to continued employment, except that the awards become fully vested upon a protected termination or a change in control. Any tranche that has not vested on or before the tenth anniversary of the effective date shall be forfeited.
Equity Transactions
Between April 1, 2026 and May 14, 2026, an aggregate of Exchangeable Shares were converted into the same number of common stock by holders of the Exchangeable Shares.
Between April 1, 2026 and May 14, 2026, the Company issued shares of common stock for vested restricted stock units, of which shares were issued to related parties, including certain executive officers and directors of the Company.
On April 10, 2026, the Company entered into an Advisory & Consulting Agreement with a third-party consultant. In connection with the agreement, the Company granted an RSU award for shares of the Company’s common stock, with RSUs vesting and issued on the effective date and the remaining RSUs vesting in two installments on the six-month and twelve-month anniversaries of the vesting commencement date, subject to continued service.
On April 6, 2026, the Company entered into a Consulting Agreement with a third-party consultant. In connection with the agreement, the Company granted an RSU award for shares of the Company’s common stock that were vested and issued on April 29, 2026.
In May 2026, the Company rescinded a previously approved equity compensation arrangement with the Company’s General Counsel covering shares of common stock. As part of this rescission, the shares were cancelled and the arrangement was terminated with no further equity compensation obligations.
| 38 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Management’s Discussion and Analysis of Financial Condition and Results of Operations includes a number of forward-looking statements that reflect Management’s current views with respect to future events and financial performance. You can identify these statements by forward-looking words such as “may,” “will,” “expect,” “anticipate,” “believe,” “estimate” and “continue,” or similar words. Those statements include statements regarding the intent, belief or current expectations of us and members of our management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.
Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission. Important factors currently known to Management could cause actual results to differ materially from those in forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions. Factors that could cause differences include, but are not limited to, expected market demand for our products, fluctuations in pricing for materials, and competition.
Business Overview
On May 28, 2025, the Company completed its acquisition of Streamex Exchange Corporation (“Streamex Exchange”). The unaudited condensed consolidated financial statements for the three months ended March 31, 2026 include the results of the Company and its consolidated subsidiaries, including Streamex Exchange, from the acquisition date, and VIE for which the Company is determined to be the primary beneficiary.
As a result of this acquisition, the Company expanded beyond its historical focus as a medical device technology company to a diversified technology platform centered on tokenized finance and the digitization of real-world assets (“RWAs”). Through Streamex Exchange, the Company has developed and operates an institutional grade technology platform that supports the tokenization of real-world assets, including gold, and other physical commodity asset interests. The Company operates as an infrastructure provider, enabling the issuance, trading, and backend infrastructure for digital tokens backed by tangible commodities, beginning with gold. The Company continues to operate its legacy medical device technology business, which focuses on healthcare technology innovation through the Company’s PURE EP™ Platform (“PURE EP™”).
The Company continues to evaluate strategic alternatives for its legacy majority-owned subsidiaries ViralClear Pharmaceuticals, Inc. (“ViralClear”) and BioSig AI Sciences, Inc. (“BioSig AI”). ViralClear’s business is currently dormant and ViralClear’s business objectives are being evaluated. BioSig AI’s business operations have currently been placed on hold.
Historically, the Company developed and commercialized advanced digital signal processing solutions for electrophysiology. PURE EP™ is designed to deliver real-time, high-fidelity cardiac signal data to electrophysiologists during ablation procedures for the treatment of cardiovascular arrhythmias. In recent periods, the Company has shifted its biomedical strategy toward research and development of proprietary software algorithms intended to enhance clinical decision-making and procedural outcomes.
Streamex Exchange has developed and operates a blockchain-based platform designed to facilitate the compliant tokenization and exchange of RWAs. As of March 31, 2026, Streamex Exchange remained in the development stage and had not generated revenue. The Company launched GLDY and began actively accepting subscriptions during Q1 2026. Future revenue generation will depend on platform maturity, regulatory developments, market conditions, adoption and issuance volumes, and the Company’s ability to monetize GLDY and additional tokenized products through fee-based services.
During the three months ended March 31, 2026, the Company, through Streamex Ltd., a Cayman Islands special-purpose entity consolidated as a variable interest entity, acquired approximately $15,225 of gold bullion to support the GLDY Token program. As of March 31, 2026, the Company held approximately 98.5% of outstanding GLDY Tokens. Two related party officers of the Company subscribed for an aggregate of approximately $225 of GLDY Tokens during March 2026.
For the three months ended March 31, 2026, the Company operated as a single reportable segment.
Results of Operations (000’s)
We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, such as the progress of our research and development and commercialization efforts, the timing and outcome of future regulatory submissions, and other macroeconomic and operational uncertainties. Due to these uncertainties, accurate predictions of future operations are difficult or impossible to make.
| 39 |
Three Months Ended March 31, 2026 Compared to Three Months Ended March 31, 2025
Revenues and Cost of Goods Sold. Revenue for the three months ended March 31, 2026 and 2025 was $0 and $0, respectively, and comprised of recognized service revenue. Historically, the Company’s revenue has been generated from sales of the PURE EP™ Platform and related support services; however, commercial activity was not significant during the year ended December 31, 2024 and did not recur in subsequent periods.
Research and Development Expenses. Research and development expenses for the three months ended March 31, 2026 were $0, a decrease of $6, or 100%, from $6 for the three months ended March 31, 2025. The decrease primarily reflects reduced research and development activity associated with the Company’s legacy medical device business as the Company has prioritized resources toward its tokenized finance platform.
General and Administrative Expenses. General and administrative expenses for the three months ended March 31, 2026 were $34,254, an increase of $31,297 or 1059%, from $2,957 incurred in the three months ended March 31, 2025. Stock-based compensation and common stock issued for services totaled $25,370 in the current period, representing approximately 74% of total general and administrative expenses, compared to $2,074 in the prior period, reflecting equity awards issued under consulting, advisory, and service arrangements. Additional increases were driven by higher professional fees, payroll, and compliance-related costs associated with expanded corporate activities during the current period.
Depreciation and Amortization Expense. Depreciation and amortization expense for the three months ended March 31, 2026 totaled $1,492, an increase of $1,471, or 7005%, over the expense of $21 incurred in the three months ended March 31, 2025, as a direct result of the amortization of the intangible assets recognized from the acquisition of Streamex Exchange. The Company’s intangible assets primarily consist of trade name, developed technology, legal and compliance framework, and patents.
Other Income (Expense), net. Other income (expense), net for the three months ended March 31, 2026 totaled $(11,513), compared to other income of $184 for the three months ended March 31, 2025. The change of $(11,697) was driven primarily by the following items, none of which existed in the prior-year period due to the May 2025 acquisition of Streamex Exchange and the November/December 2025 convertible debenture financing:
Interest expense, net, of $(12,195) consisted primarily of non-cash accretion of the debt discount and issuance costs associated with the Company’s Yorkville secured convertible debentures, which were outstanding from January 1, 2026 through their settlement on February 6, 2026.
The Company recognized a realized loss on extinguishment of convertible debentures of $(3,057) in connection with the February 2026 settlement, which included a cash payoff of $38,903 (comprised of $35,000 principal, $3,500 prepayment premium, and approximately $403 of accrued interest) and a conversion of $15,000 of principal into 3,750,000 shares. The loss represents the difference between the carrying amount of the debentures (net of unamortized discount) and the total consideration transferred.
These charges were partially offset by a realized gain on sale of gold of $2,938 from the Company’s Streamex Ltd. (VIE) gold inventory transactions, a gain of $497 from the change in fair value of the embedded derivative liability prior to its derecognition upon the February 2026 debenture settlement, and a realized gain on marketable securities of $484. The Company also recognized a realized loss on investment of $(119) and a change in fair value of marketable securities of $(134).
In the prior-year period, other income of $184 consisted primarily of a gain on settlement and forgiveness of accounts payable and other liabilities of $199.
Income taxes (benefit). For the three months ended March 31, 2026, the Company recorded an income tax benefit of $565, compared to $0 in the prior-year period. The benefit resulted from the reversal of a portion of the deferred tax liability associated with the amortization of identifiable intangible assets recognized in the Company’s acquisition of Streamex Exchange Corporation, which is held through the Company’s Canadian subsidiary. Intangible amortization for book purposes creates a temporary difference because such amortization is not deductible for Canadian income tax purposes, resulting in a deferred tax liability that reverses as the book basis of the intangible assets declines. The deferred tax liability was initially recognized as part of the acquisition accounting in May 2025 and is remeasured each period for changes in enacted tax rates and foreign currency translation. No comparable benefit was recorded in the prior-year period as the acquisition had not yet occurred.
Preferred Stock Dividend. Preferred stock dividend for the three months ended March 31, 2026 and 2025 totaled $2 and $2, respectively. Preferred stock dividends are related to the dividends accrued on our Series C Preferred Stock issued during the period from 2013 through 2015.
Net Loss Attributable to Streamex Corp. Common Stockholders. As a result of the foregoing, net loss attributable to common shareholders for the three months ended March 31, 2026 was $46,695 compared to a net loss of $2,814 for the three months ended March 31, 2025. The increase in net loss of $43,881 was primarily attributable to the changes in operating expenses, other income (expense), and income tax benefit described above.
| 40 |
Liquidity and Capital Resources and Going Concern
As of March 31, 2026, we had working capital of approximately $42,602 and cash of $6,859. For the three months ended March 31, 2026, we used $10,179 in operating activities, used $1,500 in investing activities, and used $1,637 in financing activities, primarily reflecting the repayment of the remaining outstanding balance on the secured convertible debentures of approximately $38.5 million, substantially offset by net proceeds of approximately $37.2 million from an underwritten public offering completed in January 2026.
During the three months ended March 31, 2026, the Company strengthened its liquidity position through financing transactions and asset monetization activities and eliminated its outstanding convertible debt. In January 2026, the Company completed an underwritten public offering generating net proceeds of approximately $37.2 million. The Company also received approximately $10.2 million from the sale of marketable securities and approximately $26.4 million from the sale of gold bullion that had been classified as held for sale as of December 31, 2025. In February 2026, following a partial conversion of the secured convertible debentures into common stock, the Company repaid the remaining outstanding balance for an aggregate cash payment of approximately $38.5 million, and all related security interests were released.
We expect to continue incurring operating losses and negative cash flows until our products, including the Streamex Exchange’s digital asset infrastructure and PURE EP™ Platform initiatives, achieve sustained commercial success. Although the PURE EP™ Platform is commercially available, revenues to date have not been material, and the timing and extent of future revenues remain uncertain. The Company launched GLDY and began accepting subscriptions; however, revenues to date have not been material. We expect to incur additional costs related to software development, regulatory compliance, and strategic partnerships prior to the commencement of any material revenue-generating activities. The timing and extent of any future revenues will depend on, among other things, continued investor adoption of GLDY, completion of development milestones, regulatory considerations, market conditions, and the successful commercialization of the Streamex Exchange platform and related offerings.
Based on our existing cash and working capital position, management believes that the Company has the ability to continue as a going concern for at least one year from the issuance date of the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. The Company believes it will have sufficient liquidity to meet its anticipated working capital requirements, capital expenditures, and other liquidity needs during that period.
Capital Strategy and Uses of Cash
Our capital strategy focuses on maintaining sufficient liquidity to support ongoing operations, product development, and strategic initiatives, while preserving balance sheet flexibility. We may evaluate additional capital sources from time to time, including:
| ● | Public or private equity offerings | |
| ● | Strategic partnerships or licensing arrangements | |
| ● | Government grants or non-dilutive funding | |
| ● | Debt financing, where feasible |
While we previously implemented cost-saving measures to reduce cash burn, we have increased spending to accelerate the commercialization of the Streamex Exchange platform and related initiatives. These efforts are intended to support long-term growth but will increase near-term cash requirements. There can be no assurance that any future financing, if pursued, would be available on acceptable terms.
Future financing may include the issuance of equity or debt securities, credit facilities, or other arrangements. Any such financing could result in dilution to existing stockholders or the issuance of securities with rights senior to those of our common stock. Market volatility and macroeconomic conditions may also adversely affect our ability to raise capital on acceptable terms. These financing arrangements are part of management’s broader strategy to address liquidity needs and support commercialization, research and development, and infrastructure expansion. However, there can be no assurance that financing will be available on acceptable terms, or at all.
If additional capital were required and not obtained on acceptable terms, we may be required to delay or reduce certain research and development programs, scale back commercialization efforts, or enter into strategic arrangements that could require us to relinquish rights to certain technologies or products.
Our liquidity forecast includes assumptions regarding the timing of Streamex Exchange’s development and commercialization activities, planned expenditures, and cost containment measures.
| 41 |
Financing Activities
Conversion and Repayment of Convertible debentures
On February 6, 2026, Yorkville elected to convert $15,000 of principal into shares of the Company’s common stock at a conversion price of $4.00 per share, resulting in the issuance of 3,750,000 shares. No accrued interest was converted.
Following the expiration of the conversion election period, the Company prepaid the remaining amounts outstanding under the Convertible Debentures for an aggregate cash payoff of approximately $38,903, consisting of $35,000 of principal, $3,500 of prepayment premium, and approximately $403 of accrued interest. Upon payment in full, the Convertible Debentures were satisfied and terminated, and all related security interests and liens were released.
Sale of Common Stock.
On January 22, 2026, the Company entered into an underwriting agreement with Needham & Company, LLC, as representative of the several underwriters, in connection with an underwritten public offering of the Company’s common stock. The Company issued 11,666,667 shares of common stock at a public offering price of $3.00 per share. The underwriters fully exercised their over-allotment option, resulting in the issuance of an additional 1,750,000 shares of common stock. Aggregate gross proceeds from the offering, including the over-allotment option, were approximately $40,250, before underwriting discounts, commissions, and offering expenses.
Future Capital Requirements and Risks
We expect to continue incurring expenses related to:
| ● | Expansion of business infrastructure and public company compliance | |
| ● | Integration and scaling of Streamex Exchange’s tokenization platform and digital asset infrastructure | |
| ● | Development of real-world asset (RWA) tokenization solutions, including commodities-on-chain initiatives |
Our future capital requirements will depend on several factors, including:
| ● | Progress and results of our R&D programs | |
| ● | Timing and outcome of regulatory approvals | |
| ● | Costs associated with intellectual property protection | |
| ● | Market acceptance and commercialization success | |
| ● | Availability of financing and strategic partnerships | |
| ● | Execution of Streamex Exchange’s growth strategy within the global commodities and digital asset markets | |
| ● | Infrastructure and personnel investments required to support Streamex Exchange’s platform scalability and compliance |
Critical Accounting Estimates
We prepare our unaudited condensed consolidated financial statements in accordance with GAAP, which require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. These estimates are based on historical experience, current conditions, and other factors that management believes to be reasonable under the circumstances. Actual results may differ materially from these estimates, and such differences could have a significant impact on our financial condition or results of operations.
We consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from period to period or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. There are items within our unaudited condensed consolidated financial statements that require estimation but are not deemed critical, as defined above.
Our significant accounting policies are more fully described in Note 3—Summary of Significant Accounting Policies to our unaudited condensed consolidated financial statements included in this report.
| 42 |
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not required under Regulation S-K for “smaller reporting companies.”
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of March 31, 2026. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2026, our disclosure controls and procedures were not effective due to the material weaknesses in our internal control over financial reporting described below and previously reported in our Annual Report on Form 10-K for the year ended December 31, 2025.
Material Weaknesses in Internal Control Over Financial Reporting
As disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, management identified the following material weaknesses in the Company’s internal control over financial reporting as of December 31, 2025:
| (i) | inadequate identification, recording, and reporting of stock-based compensation; | |
| (ii) | ineffective review processes over period-end financial disclosure and reporting, including review of information produced by the entity (“IPE”); | |
| (iii) | inadequate segregation of duties for transaction posting and processing; and | |
| (iv) | ineffective review controls over business combinations and related financial instruments. |
The material weaknesses did not result in any identified misstatements to the unaudited condensed consolidated financial statements and there were no changes to previously released financial results. These material weaknesses had not been remediated as of March 31, 2026, and accordingly, management concluded that our disclosure controls and procedures were not effective as of March 31, 2026.
Remediation Plan
Management has initiated and continues to execute remediation plans to address the material weaknesses described above. During the three months ended March 31, 2026, management undertook the following remediation actions:
| ● | Appointed a new Chief Financial Officer, effective March 16, 2026, to strengthen financial leadership and oversight of the accounting and reporting function; | |
| ● | Engaged external technical accounting and financial reporting advisors to assist with complex accounting matters, including stock-based compensation, business combination accounting, and derivative financial instruments; | |
| ● | Began enhancing supervisory review controls over period-end financial disclosures and reporting processes; and | |
| ● | Commenced evaluation of additional staffing and process improvements to strengthen segregation of duties within the finance and accounting function. |
Management believes these actions, once fully implemented and operating effectively for a sufficient period of time, will remediate the underlying control deficiencies. The material weaknesses will not be considered remediated until the applicable controls have operated for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. There can be no assurance that our remediation efforts will be successful or that our internal control over financial reporting will be effective as a result of these efforts.
Changes in Internal Control Over Financial Reporting
Except for the remediation actions described above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 43 |
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We may be subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.
“Item 1 - Legal Proceedings” During the fiscal quarter ended March 31, 2026, there have been no material changes from the legal proceedings discussed in our Annual Report on Form 10-K for the year ended December 31, 2025.
ITEM 1A. RISK FACTORS
In addition to other information contained elsewhere in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K filed with the SEC on March 31, 2026, or the Annual Report, which could materially affect our business, financial condition, or future results. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES
During the three months ended March 31, 2026, the Company issued the following shares of its common stock in transactions not registered under the Securities Act of 1933, as amended (the “Securities Act”):
| ● | January 2, 2026: Issued 16,015 shares of common stock upon cashless exercise of warrants to purchase 23,154 shares at a weighted average exercise price of $0.9547 per share. | |
| ● | February 26, 2026: Issued 38,632 shares of common stock upon cashless exercise of warrants to purchase 64,830 shares at a weighted average exercise price of $0.9547 per share. |
All of the above issuances were made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D, as applicable. These transactions did not involve any public offering, and the recipients represented their intent to acquire the securities for investment purposes only and not with a view to distribution.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
None.
ITEM 5. OTHER INFORMATION
None.
| 44 |
ITEM 6. EXHIBITS
* Filed herewith.
** Furnished herewith.
| 45 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| STREAMEX CORP. | ||
| Date: May 14, 2026 | By: | /s/ Henry McPhie |
| Henry McPhie | ||
| Chief Executive Officer (Principal Executive Officer) | ||
| Date: May 14, 2026 | By: | /s/ Christine Plummer |
| Christine Plummer | ||
| Chief Financial Officer (Principal Financial and Accounting Officer) | ||
| 46 |